Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 June 2022, vol.40, (Summary Text)
- Publication Type: Conference Paper / Summary Text
- Volume: 40
- Country: ELECTR NETWORK
- Trakya University Affiliated: Yes